| |
ICS cohorts (n=26,834) |
ICS/LABA cohorts (n=20,814) |
| Characteristic |
Switch to QD
(n=941) |
Remain on BD
(n=25,893) |
p value* |
Switch to QD
(n=505) |
Remain on BD
(n=20,309) |
p value* |
| Year of index prescription, mean (SD) |
2000.8 (4.7) |
1999.6 (4.3) |
<0.001 |
2003.4 (3.6) |
2003.2 (3.3) |
0.002 |
| ICS drug prescribed at the index date |
|
|
|
|
|
|
| Beclomethasone |
353 (37.5) |
18,249 (70.5) |
<0.001 |
48 (9.5) |
5474 (27.0) |
<0.001 |
| Fluticasone |
130 (13.8) |
2790 (10.8) |
|
184 (36.4) |
9309 (45.8) |
|
| Mometasone |
53 (5.6) |
10 (0.0) |
|
20 (4.0) |
19 (0.1) |
|
| Budesonide |
272 (28.9) |
4841 (18.7) |
|
126 (25.0) |
5495 (27.1) |
|
| Ciclesonide |
133 (14.1) |
3 (0.0) |
|
127 (25.1) |
12 (0.1) |
|
| ICS dose† prescribed at the index date, n (%) |
|
|
|
|
|
|
| ≤ 200 µg/day |
748 (79.5) |
13,758 (53.1) |
<0.001 |
331 (65.5) |
5091 (25.1) |
<0.001 |
| 201-400 µg/day |
145 (15.4) |
10,100 (39.0) |
|
75 (14.9) |
8827 (43.5) |
|
| >400 µg/day |
48 (5.1) |
2035 (7.9) |
|
99 (19.6) |
6391 (31.5) |
|
| Percentage step-down in ICS dose, n (%) |
|
|
|
|
|
|
| 50% |
493 (52.4) |
20,093 (77.6) |
<0.001 |
237 (46.9) |
12,079 (59.5) |
<0.001 |
| >50% |
448 (47.6) |
5800 (22.4) |
|
268 (53.1) |
8230 (40.5) |
|
*χ2 test; †The ICS dose is the beclomethasone dipropionate-equivalent.
BD: Twice Daily; ICS: Inhaled Corticosteroid; LABA: Long-Acting β-Agonist; QD: Once Daily |
